Bristol-Myers’s Reliance on Three Drugs Casts Doubt on Strategy

Wednesday, January 28, 2009 - 00:42 in Psychology & Sociology

Bristol-Myers Squibb’s current strategy is to move away from mass-market drugs into more expensive drugs for rarer diseases. But more than half its sales depend on three drugs alone.

Read the whole article on NY Times Health

More from NY Times Health

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net